| |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Previous Article | Next Article ![]()
Clinical and Vaccine Immunology, May 2007, p. 638-640, Vol. 14, No. 5
1071-412X/07/$08.00+0 doi:10.1128/CVI.00479-06
Copyright © 2007, American Society for Microbiology. All Rights Reserved.

MiraVista Diagnostics, Indianapolis, Indiana,1 National Cancer Institute, Pediatric Oncology Branch, Immunocompromised Host Section, CRC, Rm. 1W-5750, 10 Center Drive, Bethesda, Maryland 20892-1100,2 Laboratory Animal Sciences Program, SAIC-Frederick, Inc., Frederick, Maryland 21702,3 Indiana University School of Medicine, Department of Pulmonary Medicine, Roudebush Veterans' Administration Hospital, 1481 West Tenth Street, Indianapolis, Indiana 462024
Received 19 December 2006/ Returned for modification 24 January 2007/ Accepted 8 February 2007
We observed false-positive results in the Platelia Aspergillus enzyme-linked immunoassay (EIA) for specimens from patients with histoplasmosis and mice with experimental infection. Platelia Aspergillus EIA-positive specimens were negative in the second-generation Histoplasma antigen EIA. Care must be taken to exclude histoplasmosis for patients with positive Platelia Aspergillus EIA results.
Published ahead of print on 7 March 2007.
This article has been cited by other articles:
| Antimicrob. Agents Chemother. | Clin. Microbiol. Rev. | Infect. Immun. |
|---|---|---|
| J. Clin. Microbiol. | J. Virol. | ALL ASM JOURNALS |